Announcements Trials
Browse Landscape

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 2232Neoplasms 2038Lung Neoplasms 1096Colorectal Neoplasms 1036Prostatic Neoplasms 894Carcinoma, Non-Small-Cell Lung 752Carcinoma, Hepatocellular 673Stomach Neoplasms 607Pancreatic Neoplasms 602Head and Neck Neoplasms 434Ovarian Neoplasms 430Colonic Neoplasms 423Rectal Neoplasms 406Uterine Cervical Neoplasms 403Esophageal Neoplasms 346Brain Neoplasms 329Neoplasm Metastasis 324Melanoma 306Multiple Myeloma 304Precursor Cell Lymphoblastic Leukemia-Lymphoma 293Urinary Bladder Neoplasms 290Leukemia, Myeloid, Acute 278Lymphoma 268Liver Neoplasms 253Endometrial Neoplasms 253Hematologic Neoplasms 252Disease 244Recurrence 225Glioma 218Carcinoma, Renal Cell 207

Interventions

rasburicase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Observational × Tumor Lysis Syndrome × Clear all
NCT05840289 2023-05-06

FRILLY

University Hospital, Geneva

Unknown
94 enrolled

Tumor Lysis Syndrome

NCT00186940 2017-04-25

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

St. Jude Children's Research Hospital

Completed
16 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡